Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TripleTRE: Initial Triple Therapy vs Double Oral Therapy in PAH
NCT06317805Phase 4Recruiting
- Sponsor
- AOP Health
- Start
- Dec 2023
- Primary completion
- Jun 2027
- Modality
- Orthosteric Ligands
- Countries
- 12
01
Overview
A Phase 4 trial of treprostinil in pulmonary arterial hypertension (PAH), sponsored by AOP Health. Started Dec 2023; status: recruiting.
02
Drugs
treprostinil
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT06317805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06317805.